Brokerages predict that GALAPAGOS NV/S (NASDAQ:GLPG) will announce $2.37 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for GALAPAGOS NV/S’s earnings. The lowest EPS estimate is ($1.80) and the highest is $9.17. GALAPAGOS NV/S reported earnings per share of $0.33 in the same quarter last year, which would indicate a positive year over year growth rate of 618.2%. The company is scheduled to announce its next earnings report on Friday, October 25th.

On average, analysts expect that GALAPAGOS NV/S will report full year earnings of $3.29 per share for the current year, with EPS estimates ranging from ($4.46) to $9.54. For the next fiscal year, analysts forecast that the business will post earnings of ($1.16) per share, with EPS estimates ranging from ($6.63) to $3.22. Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for GALAPAGOS NV/S.

A number of brokerages have recently issued reports on GLPG. Credit Suisse Group reaffirmed an “outperform” rating on shares of GALAPAGOS NV/S in a research report on Wednesday, July 10th. BidaskClub raised GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. UBS Group raised GALAPAGOS NV/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, July 31st. Jefferies Financial Group downgraded GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Monday, July 29th. Finally, Zacks Investment Research downgraded GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $156.45.

Shares of GLPG stock traded down $0.02 during trading hours on Thursday, reaching $169.57. 85,675 shares of the company’s stock were exchanged, compared to its average volume of 132,951. The business’s 50 day moving average price is $160.89. The stock has a market cap of $8.96 billion, a P/E ratio of -256.92 and a beta of 1.57. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.02. GALAPAGOS NV/S has a fifty-two week low of $85.00 and a fifty-two week high of $191.63.

Several institutional investors and hedge funds have recently made changes to their positions in the company. FDx Advisors Inc. grew its holdings in shares of GALAPAGOS NV/S by 5.6% during the second quarter. FDx Advisors Inc. now owns 2,154 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 115 shares during the last quarter. Comerica Bank grew its holdings in shares of GALAPAGOS NV/S by 4.1% during the second quarter. Comerica Bank now owns 3,036 shares of the biotechnology company’s stock valued at $516,000 after buying an additional 120 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of GALAPAGOS NV/S by 170.7% during the second quarter. Tower Research Capital LLC TRC now owns 249 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 157 shares during the last quarter. Macquarie Group Ltd. grew its holdings in shares of GALAPAGOS NV/S by 2.7% during the fourth quarter. Macquarie Group Ltd. now owns 7,768 shares of the biotechnology company’s stock valued at $713,000 after buying an additional 202 shares during the last quarter. Finally, Castleark Management LLC grew its holdings in shares of GALAPAGOS NV/S by 4.5% during the second quarter. Castleark Management LLC now owns 8,650 shares of the biotechnology company’s stock valued at $1,115,000 after buying an additional 370 shares during the last quarter. 17.06% of the stock is currently owned by hedge funds and other institutional investors.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Story: What are earnings reports?

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.